Research gaps in neonatal HIV-related care

Southern African Journal of HIV Medicine

Volumn 16, Issue 1, 2015, Pages

  Davies, Mary Ann ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ANTIVIRAL THERAPY; CHILD SAFETY; CLINICAL RESEARCH; DISEASE COURSE; HIGH RISK INFANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LABORATORY DIAGNOSIS; NEWBORN CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN PERIOD; NONHUMAN; PERINATAL PERIOD; POLYMERASE CHAIN REACTION; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PROGRAM DEVELOPMENT; PUERPERIUM; REVIEW; SOUTH AFRICAN; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 84930839835     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.4102/sajhivmed.v16i1.375     Document Type: Review

References (87)

1. Barron P, Pillay Y, Doherty T, et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Org. 2013;91:70-74. http://dx.doi.org/10.2471/BLT.12.106807.
2. Goga AE, Dinh TH, Jackson DJ, et al. First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child, South Africa. J Epidemiol Community Health. 2015;69:240-248. http://dx.doi.org/10.1136/jech-2014-204535.
3. Guidelines for the management of HIV in children. 2nd ed. Pretoria: Department of Health; 2010.
4. Circular minute 2 of 2012: Initiation of antiretroviral treatment to all HIV positive children aged 5 years and under regardless of CD4 count and/or WHO clinical staging. Pretoria: Department of Health; 2012.
5. Report of the WHO technical reference group, paediatric HIV/ART care guideline meeting. c2008 [cited 15 September 2008]. Available from: http://www.who.int/hiv/pub/meetingreports/art-meeting-april2008/en/index.html.
6. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach: 2010 revision. c2010 [cited 19 October 2010]. Available from: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html.
7. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Summary of key features and recommendations. c2013 [cited 10 November 2013]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/short-summary/en/index.html.
8. Davies M, Phiri S, Wood R, et al. Temporal trends in the characteristics of children at antiretroviral therapy initiation in Southern Africa: The International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration. PLoS One. 2013;8:e81037. http://dx.doi.org/10.1371/journal.pone.0081037.
9. Porter M, Davies M, Mapani M, et al. Outcomes of infants starting antiretroviral therapy in Southern Africa, 2004 - 2012. Paper presented at: Southern African HIV Clinicians Society Conference; 2014; Cape Town.
10. Fatti G, Eley B, Grimwood A. Outcomes of infants starting treatment at routine facilities supported by a non-profit organization in South Africa. Paper presented at: Southern African HIV Clinicians Society Conference; 2014; Cape Town.
11. Mugglin C, Wandeler G, Estill J, et al. Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: Systematic review. PLoS One. 2013;8:e56446. http://dx.doi.org/10.1371/journal.pone.0056446.
12. Feucht UD, Kinzer M, Kruger M. Reasons for delay in initiation of antiretroviral therapy in a population of HIV-infected South African children. J Trop Pediatr. 2007;53:398-402. http://dx.doi.org/10.1093/tropej/fmm060.
13. Innes S, Lazarus E, Otwombe K, et al. Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late? J Int AIDS Soc. 2014;17:18914. http://dx.doi.org/10.7448/IAS.17.1.18914.
14. Kroon SM. Recognising and managing increased HIV transmission risk in newborns. Southern African Journal of HIV Medicine. In press 2015.
15. Sherman G. HIV testing during the neonatal period. Southern African Journal of HIV Medicine. In press 2015.
16. Nuttall J. Antiretroviral therapy during the neonatal period. Southern African Journal of HIV Medicine. In press 2015.
17. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). Update May 2014. London: British HIV Association; 2014.
18. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Medicine. 2012;13:87-157. http://dx.doi.org/10.1111/j.1468-1293.2012.01030.x.
19. US Department of Health and Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. c2014 [cited 08 January 2015]. Available from: http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/.
20. Kuhn L, Abrams EJ, Matheson PB, et al. Timing of maternal-infant HIV transmission: Associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS. 1997;11:429-435. http://dx.doi.org/10.1097/00002030-199704000-00005.
21. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005;38:87-95. http://dx.doi.org/10.1097/00126334-200501010-00016.
22. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362:1171-1177. http://dx.doi.org/10.1016/S0140-6736(03)14538-2.
23. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366:2368- 2379. http://dx.doi.org/10.1056/NEJMoa1108275.
24. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV- 1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 2012;160:60-66. http://dx.doi.org/10.1016/j.jpeds.2011.06.053.
25. Haeri Mazanderani AF, Du Plessis NM, Thomas WN, Venter E, Avenant T. Loss of detectability and indeterminate results: Challenges facing HIV infant diagnosis in South Africa's expanding ART programme. S Afr Med J. 2014;104:574-577. http://dx.doi.org/10.7196/samj.8322.
26. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. c2014 [cited 15 January 2015]. Available from: http://www.health.gov.za/policies.php.
27. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. c2014 [cited 01 April 2014]. Available from: http://www.who.int.
28. Lilian RR, Kalk E, Bhowan K, et al. Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. J Clin Microbiol. 2012;50:2373-2377. http://dx.doi.org/10.1128/JCM.00431-12.
29. Penazzato M, Revill P, Prendergast AJ, et al. Early infant diagnosis of HIV infection in low-income and middle-income countries: Does one size fit all? Lancet Infect Dis. 2014;14:650-655. http://dx.doi.org/10.1016/S1473-3099(13)70262-7.
30. Lilian RR, Johnson LF, Moolla H, Sherman GG. A mathematical model evaluating the timing of early diagnostic testing in HIV-exposed infants in South Africa. J Acquir Immune Defic Syndr. 2014;67:341-348. http://dx.doi.org/10.1097/QAI.0000000000000307.
31. Mitchell C, Dross S, Beck IA, Micek MA, Frenkel LM. Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs. Clin Infect Dis. 2014;58:1190-1193. http://dx.doi.org/10.1093/cid/ciu068.
32. Levin M, Mathema H, Stinson K, Jennings K. Acceptability, feasibility and impact of routine screening to detect undiagnosed HIV infection in 17 - 24-month-old children in the Western sub-district of Cape Town. S Afr Med J. 2012;102: 245-248.
33. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244. http://dx.doi.org/10.1056/NEJMoa0800971.
34. Nelson A, Cox V, Frigati LJ, et al. Feasibility of early infant HIV diagnosis and ART initiation in primary and tertiary care settings in Cape Town, South Africa. Paper presented at: Southern African HIV Clinicians Society Conference; 2014; Cape Town.
35. Rollins N, Mzolo S, Moodley T, Esterhuizen T, Van Rooyen H. Universal HIV testing of infants at immunization clinics: An acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings. AIDS. 2009;23:1851-1857. http://dx.doi.org/10.1097/QAD.0b013e32832d84fd.
36. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: Opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011;9:59. http://dx.doi.org/10.1186/1741-7015-9-59.
37. Hsiao NY, Stinson K, Myer L. Linkage of HIV-infected infants from diagnosis to antiretroviral therapy services across the Western Cape, South Africa. PLoS One. 2013;8:e55308. http://dx.doi.org/10.1371/journal.pone.0055308.
38. Smith SJ, Nimmo C, Fredlund V, Moodley P. Early infant diagnosis of HIV and fast initiation of anti-retroviral therapy in a rural African setting: How well are we doing? Paediatr Int Child Health. 2014;34:203-207. http://dx.doi.org/10.1179/2046905514Y.0000000119.
39. Jani IV, Meggi B, Mabunda N, et al. Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr. 2014;67:e1-4. http://dx.doi.org/10.1097/QAI.0000000000000250.
40. Hsiao NY, Dunning L, Kroon SM, Myer L. Evaluation of the Alere q point-of-care system for early infant diagnosis. Paper presented at: Conference on Retroviruses and Opportunistic Infections; 2015; Seattle, USA.
41. Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS. 2012;26:1483-1490. http://dx.doi.org/10.1097/QAD.0b013e3283553638.
42. Abrams EJ, Kuhn L. Should treatment be started among all HIV-infected children and then stopped? Lancet. 2003;362:1595-1596. http://dx.doi.org/10.1016/S0140-6736(03)14837-4.
43. Shiau S, Kuhn L. Antiretroviral treatment in HIV-infected infants and young children: Novel issues raised by the Mississippi baby. Expert Rev Anti Infect Ther. 2014;12:307-318. http://dx.doi.org/10.1586/14787210.2014.888311.
44. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: Results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013;382:1555-1563. http://dx.doi.org/10.1016/S0140-6736(13)61409-9.
45. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol. 2000;74:6984- 6991. http://dx.doi.org/10.1128/JVI.74.15.6984-6991.2000.
46. Bourne DE, Thompson M, Brody LL, et al. Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. AIDS. 2009;23:101-106. http://dx.doi.org/10.1097/QAD.0b013e32831c54bd.
47. Marston M, Becquet R, Zaba B, et al. Net survival of perinatally and postnatally HIV-infected children: A pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol. 2011;40:385-396. http://dx.doi.org/10.1093/ije/dyq255.
48. Mphatswe W, Blanckenberg N, Tudor-Williams G, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis 10. AIDS. 2007;19:1253-1261. http://dx.doi.org/10.1097/QAD.0b013e3281a3bec2.
49. HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1- infected children. AIDS. 2006;20:1289-1294. http://dx.doi.org/10.1097/01.aids.0000232237.20792.68.
50. Rabie H, Violari A, Duong T, et al. Early antiretroviral treatment reduces risk of bacille Calmette-Guerin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011;15:1194-1200. http://dx.doi.org/10.5588/ijtld.10.0721.
51. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS. 2012;26:1685-1690. http://dx.doi.org/10.1097/QAD.0b013e328355d0ce.
52. Goetghebuer T, Le Chenadec J, Haelterman E, et al. Short- And long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis. 2012;54:878-881. http://dx.doi.org/10.1093/cid/cir950.
53. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis. 2014;210:1529-1538. http://dx.doi.org/10.1093/infdis/jiu297.
54. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471-2480. http://dx.doi.org/10.1056/NEJMoa032706.
55. Newell ML, Patel D, Goetghebuer T, Thorne C. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: Is it associated with age at initiation? J Infect Dis. 2006;193:954-962. http://dx.doi.org/10.1086/500842.
56. Picat MQ, Lewis J, Musiime V, et al. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub- Saharan Africa: A cohort-based modelling study. PLoS Med. 2013;10:e1001542. http://dx.doi.org/10.1371/journal.pmed.1001542.
57. Chiappini E, Galli L, Tovo PA, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS. 2006;20:207-215. http://dx.doi.org/10.1097/01.aids.0000200529.64113.3e.
58. Shiau S, Arpadi S, Strehlau R, et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013;162:1138-1145. http://dx.doi.org/10.1016/j.jpeds.2012.11.025.
59. Crowell C, Huo Y, Tassiopoulos K, et al. Early viral suppression improves neurocognitive outcomes in HIV-infected children. Paper presented at: Conference on Retroviruses and Opportunistic Infections; 2014; Boston.
60. Li JZ, Gandhi RT. The sooner, the better: More evidence that early antiretroviral therapy lowers viral reservoirs in HIV-infected infants. J Infect Dis. 2014;210:1519- 1522. http://dx.doi.org/10.1093/infdis/jiu298.
61. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369:1828-1835. http://dx.doi.org/10.1056/NEJMoa1302976.
62. Giacomet V, Trabattoni D, Zanchetta N, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet. 2014;384:1320. http://dx.doi.org/10.1016/S0140-6736(14)61405-7.
63. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J. 23 September 2014. [Epub ahead of print].
64. Ackermann C, Andronikou S, Laughton B, et al. White matter signal abnormalities in children with suspected HIV-related neurologic disease on early combination antiretroviral therapy. Pediatr Infect Dis J. 2014;33:e207-e212. http://dx.doi.org/10.1097/INF.0000000000000288.
65. Holgate SL, Rabie H, Smith P, Cotton MF. Trough lopinavir concentrations in preterm HIV-infected infants. Pediatr Infect Dis J. 2012;31:602-604. http://dx.doi.org/10.1097/INF.0b013e31825046ae.
66. Mirpuri J, Jain L. Issues of prematurity and HIV infection. Clin Perinatol. 2010;37:887-905. http://dx.doi.org/10.1016/j.clp.2010.08.012.
67. Little K, Thorne C, Luo C, et al. Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: Reviewing the need for HIV treatment. Current HIV Research. 2007;5:139-153. http://dx.doi.org/10.2174/157016207780077002.
68. Kuhn L, Hunt G, Technau KG, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014;28:1673-1678. http://dx.doi.org/10.1097/QAD.0000000000000261.
69. Fisher RG, Smith DM, Murrell B, et al. Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure. J Clin Virol. 2015;62:48-53. http://dx.doi.org/10.1016/j.jcv.2014.11.014.
70. Kekitiinwa A, Cook A, Nathoo K, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial. Lancet. 2013;381:1391-1403. http://dx.doi.org/10.1016/S0140-6736(12)62198-9.
71. Judd A, for the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: Treatment response and duration of first-line regimens. AIDS. 2011;25:2279-2287.
72. Goossens C, Technau K. A descriptive case series of HIV-positive infants started on antiretroviral treatment within the first six weeks of life at Rahima Moosa Mother and Child Hospital. Paper presented at: Southern African HIV Clinicians Society Conference; 2014; Cape Town.
73. Pillay S, Kroon SM, Hsaio NY, Nuttall J. Neonatal HIV case series: Challenges in diagnosis and mnagement. Paper presented at: Southern African Paediatric Association Congress; 2014; Cape Town.
74. Chadwick EG, Pinto J, Yogev R, et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: Pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J. 2009;28:215-219. http://dx.doi.org/10.1097/INF.0b013e31818cc053.
75. Ibeto M, Giddy J, Cox V. Closing the gaps: Steps towards elimination of mother-to-child transmission of HIV. S Afr J HIV Med. 2014;15:107-109. http://dx.doi.org/10.7196/sajhivmed.1047.
76. Mnyani CN, Simango A, Murphy J, Chersich M, McIntyre JA. Patient factors to target for elimination of mother-to-child transmission of HIV. Global Health. 2014;10:36. http://dx.doi.org/10.1186/1744-8603-10-36.
77. Feucht UD, Meyer A, Kruger M. Missing HIV prevention opportunities in South African children - A 7-year review. BMC Public Health. 2014;14:1265. http://dx.doi.org/10.1186/1471-2458-14-1265.
78. Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin Infect Dis. 2014;59:1012-1019. http://dx.doi.org/10.1093/cid/ciu432.
79. Lilian RR, Kalk E, Technau KG, Sherman GG. Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission. Pediatr Infect Dis J. 2013;32:1080-1085. http://dx.doi.org/10.1097/INF.0b013e318290622e.
80. Tartakovsky E, Hamama L. Mothers' acceptance-rejection of their children infected with HIV: The role of the mothers' social axioms, psychological distress, and relationships with the partner. J Pediatr Psychol. 2011;36:1030-1042. http://dx.doi.org/10.1093/jpepsy/jsr032.
81. Oswalt KL, Biasini FJ. Characteristics of HIV-infected mothers associated with increased risk of poor mother-infant interactions and infant outcomes. J Pediatr Health Care. 2012;26:83-91. http://dx.doi.org/10.1016/j.pedhc.2010.06.014.
82. Varga CA, Sherman GG, Maphosa J, Jones SA. Psychosocial consequences of early diagnosis of HIV status in vertically exposed infants in Johannesburg, South Africa. Health Care Women Int. 2005;26:387-397. http://dx.doi.org/10.1080/07399330590933935.
83. Varga CA, Sherman GG, Jones SA. HIV-disclosure in the context of vertical transmission: HIV-positive mothers in Johannesburg, South Africa. Aids Care. 2006;18:952-960. http://dx.doi.org/10.1080/09540120500356906.
84. Shah SK, Persaud D, Wendler DS, et al. Research into a functional cure for HIV in neonates: The need for ethical foresight. Lancet Infect Dis. 2014;14:893-898. http://dx.doi.org/10.1016/S1473-3099(14)70766-2.
85. Eley B, Nuttall J, Davies MA, et al. Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents. S Afr Med J. 2004;94:643-646.
86. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905-1913. http://dx.doi.org/10.1097/00002030-200409240-00006.
87. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489. http://dx.doi.org/10.1016/S1473-3099(08)70180-4.